According to the company, the market for stem cell technology is currently $500 million, and has been estimated to grow to $30 billion by the year 2010 due to the growth of new cellular therapeutics as well as clinical applications.
LifeStem’s strategy is to leverage CalbaTech’s infrastructure of companies to obtain a leadership position in the emerging stem cells arena and become a preferred provider of adult stem cells to the clinical researcher as part of a comprehensive package of stem cell based services.
The company is focused on providing a stem cell banking service to affluent individuals; providing services and technologies to facilitate the efficient acquisition and delivery of purified adult stem cells to the research market; developing delivery devices for clinical applications, and developing clinical applications of specific stem cell based therapies.